Society for Neuro-Oncology
Among patients with a performance status of less than 80, 20.6% had an improvement in this metric.
The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.
Patient satisfaction scores before the pandemic were comparable to scores during the pandemic.
Next post in SNO 2022
Loading...
Loading...